

SCREENPOINT

Medical



Advancing early detection and diagnosis of breast cancer



Breast cancer – a global problem

- Radiologists miss up to 25% of visible cancers in screening mammograms
- Fewer radiologists
- Increase in workload due to introduction of 3D mammography
- Personalised screening increases need for effective risk assessment tools

Source: GLOBOCAN 2018


One in eight women will be diagnosed with breast cancer in Western countries



Worldwide increase from 2.1 (2018) to 3.1 million cases (by 2040)

Existing solutions not effective / sustainable


- Double reading
- Recall more women for additional exams
- Computer Aided Detection



CAD was introduced 20 years ago in mammography

Transpara® is the first FDA cleared Deep Learning solution in 2D and 3D mammography

Regular 2D Mammogram




Technology and Algorithm

- Algorithms trained on over **1,000,000** images
- Curated databases with populations from **12** countries and **3** continents

Digital Breast Tomosynthesis

Up to 300 slices per exam



Synthetic 2D



Negative DBT screening exam



Women later diagnosed with an interval cancer.

Negative DBT screening exam

Risk Score 10



Women later diagnosed with an interval cancer.

Studies demonstrate superior performance of Transpara



JNCI J Natl Cancer Inst (2019) 111(9): djy222

doi: 10.1093/jnci/djy222
Article

ARTICLE

Stand-Alone Artificial Intelligence for Breast Cancer Detection in Mammography: Comparison With 101 Radiologists

Alejandro Rodriguez-Ruiz, Kristina Lång, Albert Gubern-Merida, Mireille Broeders, Gisella Gennaro, Paola Clauser, Thomas H. Helbich, Margarita Chevalier, Tao Tan, Thomas Mertelmeier, Matthew G. Wallis, Ingvar Andersson, Sophia Zackrisson, Ritse M. Mann, Ioannis Sechopoulos

Radiology

ORIGINAL RESEARCH • BREAST IMAGING

Detection of Breast Cancer with Mammography: Effect of an Artificial Intelligence Support System


Alejandro Rodriguez-Ruiz, MSc • Elizabeth Krupinski, PhD • Jan-Jurre Mondag, MSc • Kathy Schilling, MD • Sylvia H. Heywang-Köbrunner, MD, PhD • Ioannis Sechopoulos, PhD • Ritse M. Mann, MD, PhD

From the Department of Radiology and Nuclear Medicine, Radboud University Medical Center, PO Box 9101, 6500 HB Nijmegen, Geert Grooteplein 10, 6525 GA, Post 766, Nijmegen, the Netherlands (A.R.R., L.S., R.M.M.); Department of Radiology & Imaging Sciences, Emory University, Atlanta, Ga (E.K.); ScreenPoint Medical BV, Nijmegen, the Netherlands (J.J.M.); Lynn Women's Health & Wellness Institute, Boca Raton Regional Hospital, Boca Raton, Fla (K.S.); Referenzzentrum Mammographie München, Brustdiagnostik München and FFB, Munich, Germany (S.H.H.); and Dutch Expert Centre for Screening, Nijmegen, the Netherlands (L.S.). Received June 10, 2018; revision requested July 30; final revision received September 21; accepted September 28. Address correspondence to R.M.M. (e-mail: Ritse.Mann@radboudumc.nl).

Conflicts of interest are listed at the end of this article.

See also the editorial by Bahl in this issue.

Radiology 2019; 00:1–10 • <https://doi.org/10.1148/radiol.2018181371> • Content code: BR



ScreenPoint Founded in 2014 as spin-out of Radboudumc



Nico Karssemeijer

Professor at Radboud University
Co-founder QView (CA) and Volpara
(NZ)



Mike Brady

Professor at Oxford University
Co-founder Perspectum (UK), Volpara
(NZ), Mirada (UK)



Carl Evertsz

Previously CEO of MeVis Medical
Solutions



Startup - phase

- Preparation (1 year)
 - Make business plan
 - Form a team (students and co-founder)
 - Get permission (and keep position as professor)
 - Negotiate license agreement with
- Foundation and Startup (May 2014)
 - Initial funding from founders
 - 3 employees
 - Rented office space in “Mercator Launch” (Toernooiveld 100)
- Support
 - SMB (advise John Schalken, kleine ‘kraamkamer’ subsidie)
 - Valorisation



Startup – phase II (2017-2019)

- Developing Algorithms
- Expanding the team to 20 employees
- Clinical studies
- Regulatory clearance (CE, FDA)
- Key publications with researchers at Radboudumc
- Funding round with Siemens Healthineers as lead investor



Scaling up

- Back to the campus
- Expanding the team to 40 employees
- Building relations with KOLs
- Expanding evidence
- First customers
- Regulatory clearance DBT
- Setting up sales network (direct and through distributors)



ScreenPoint now: Global presence and leading AI company in breast imaging

